{"created":"2023-06-19T10:43:22.467187+00:00","id":3602,"links":{},"metadata":{"_buckets":{"deposit":"c74e9075-9bb9-421e-83b3-75a97361df50"},"_deposit":{"created_by":11,"id":"3602","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"3602"},"status":"published"},"_oai":{"id":"oai:shiga-med.repo.nii.ac.jp:00003602","sets":["30:59:221"]},"author_link":["7969","7967","7968","3054","7970","4365"],"item_4_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-04-24","bibliographicIssueDateType":"Issued"},"bibliographicVolumeNumber":"11","bibliographic_titles":[{},{"bibliographic_title":"Frontiers in Endocrinology","bibliographic_titleLang":"en"}]}]},"item_4_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"藤田, 征弘"}],"nameIdentifiers":[{},{},{}]}]},"item_4_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Objective: \nWe recently observed a greater increase in plasma levels of bioactive glucose-dependent insulinotropic polypeptide (GIP) than glucagon-like peptide 1 (GLP-1) using the receptor-mediated bioassays in the subjects with normal glycemic tolerance (NGT) treated with dipeptidyl peptidase 4 (DPP-4) inhibitors, which may be unappreciated using conventional enzyme-linked immunosorbent assays (ELISAs) during oral glucose tolerance test. Thus, we determined incretin levels in addition to glucagon level using the bioassays in type 2 diabetes mellitus (T2DM) subjects with or without treatment of DPP-4 inhibitor, to evaluate whether these assays can accurately measure bioactivity of these peptides.","subitem_description_type":"Abstract"},{"subitem_description":"Methods: \nWe performed single meal tolerance test (MTT) by using a cookie meal (carbohydrate 75.0 g, protein 8.0 g, fat 28.5 g) in the subjects with NGT (n = 9), the subjects with T2DM treated without DPP-4 inhibitor (n = 7) and the subjects with T2DM treated with DPP-4 inhibitor (n = 10). All subjects fasted for 10-12 h before the MTT, and blood samples were collected at 0, 30, 60, and 120 min. We used the cell lines stably cotransfected with human-form GIP, GLP-1 or glucagon receptor, and a cyclic adenosine monophosphate-inducible luciferase expression construct for the bioassays. We measured active GIP, active GLP-1, and glucagon by the bioassays. To evaluate the efficacy of bioassay, we measured identical samples via ELISA kits. ","subitem_description_type":"Abstract"},{"subitem_description":"Results: \nDuring the single MTT study, postprandial active GIP bioassay levels of T2DM with DPP-4 inhibitor treatment were drastically higher than those of NGT and T2DM without DPP-4 inhibitor, although the DPP-4 inhibitor-treated group showed moderate increase of active GIPELISA and active GLP-1 bioassay , while active GLP-1 bioassay levels of T2DM subjects without DPP-4 inhibitor were comparable to those of NGT subjects. During the serial MTT, administration of DPP-4 inhibitor significantly increased active GIP bioassay levels, but not active GLP-1 bioassay . ","subitem_description_type":"Abstract"},{"subitem_description":"Conclusions: \nIn comparison to conventional ELISA, receptor-mediated bioassay reflects dynamic change of GIP polypeptide by DPP-4 inhibitor treatment in subjects with type 2 diabetes. ","subitem_description_type":"Abstract"}]},"item_4_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Journal Article","subitem_description_type":"Other"}]},"item_4_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Frontiers Research Foundation"}]},"item_4_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.3389/fendo.2020.00214"}],"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.3389/fendo.2020.00214","subitem_relation_type_select":"DOI"}}]},"item_4_relation_13":{"attribute_name":"PMCID","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"PMC7193081"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7193081/","subitem_relation_type_select":"URI"}}]},"item_4_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2020 Yanagimachi, Fujita, Takeda, Honjo, Yokoyama and Haneda. "}]},"item_4_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"YANAGIMACHI, Tsuyoshi"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"FUJITA, Yukihiro"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"TAKEDA, Yasutaka"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"HONJO, Jun"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"YOKOYAMA, Hiroki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"HANEDA, Masakazu"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-06-17"}],"displaytype":"detail","filename":"fendo.2020.00214 .pdf","filesize":[{"value":"728.1 kB"}],"format":"application/pdf","license_note":"© 2020 Yanagimachi, Fujita, Takeda, Honjo, Yokoyama and Haneda. \nThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"fendo.2020.00214 ","url":"https://shiga-med.repo.nii.ac.jp/record/3602/files/fendo.2020.00214 .pdf"},"version_id":"155a624f-52d9-4859-9c1a-f63c46d47db2"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"dipeptidyl peptidase 4","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"glucagon","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"glucagon-like peptide 1","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"glucose-dependent insulinotropic polypeptide","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"receptor-mediated bioassay","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes."}]},"item_type_id":"4","owner":"11","path":["221"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-06-17"},"publish_date":"2020-06-17","publish_status":"0","recid":"3602","relation_version_is_last":true,"title":["Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes."],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-06-19T12:18:27.550742+00:00"}